Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo PeLeMM: Neoadjuvant Pembrolizumab and Lenvatinib in Mucosal Melanoma
NCT05545969Phase 2Withdrawn
- Sponsor
- Melanoma Institute Australia
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in mucosal melanoma (MM), sponsored by Melanoma Institute Australia. Planned start Mar 2024; status: withdrawn.
02
Drugs
pembrolizumablenvatinib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT05545969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545969.